AGENUS INC (AGEN) Stock News
NASDAQ:AGEN - Nasdaq - US00847G8042 - Common Stock - Currency: USD
AGEN Latest News, Press Relases and Analysis
SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal
SPRO shares surge after GSK-partnered oral drug hits phase III goal early, paving the way for FDA filing and a shift in cUTI treatment options.
U.S. Govt. Cancels $766M Funding Contract for Moderna's Bird Flu Shot
The government scraps funding deal for MRNA's bird flu shot, despite encouraging safety and efficacy data from early clinical studies on the vaccine.
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz
BMRN's acquisition of INZY is set to add a late-stage enzyme replacement therapy for a rare genetic condition. The deal is likely to be closed by September.
Despite Fast-paced Momentum, Agenus (AGEN) Is Still a Bargain Stock
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Agenus (AGEN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer
Following the approval, ABBV's Emrelis becomes the first FDA-approved therapy for previously treated advanced NSCLC patients with high c-Met protein overexpression.
Allogene's Q1 Earnings In Line With Estimates, Sales Nil
ALLO's first-quarter earnings match estimates. Devoid of marketed products, the company records nil sales in the quarter.
Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates
Agenus (AGEN) delivered earnings and revenue surprises of 36.02% and 14.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: LXRX
Agenus Reports Q1 2025 Financial Results and Key Business Updates
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?
Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year.
Mentions: ANIP
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
MannKind (MNKD) delivered earnings and revenue surprises of 33.33% and 5.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: MNKD
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -6.02% and 84.51%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: VIR
Waters Q1 Earnings Surpass Estimates, Revenue Rise Y/Y
WAT's first-quarter 2025 results reflect strong growth in the instruments and chemical segments, coupled with strong momentum in the industrial and pharma sectors.
Vertex Pharmaceuticals (VRTX) Misses Q1 Earnings and Revenue Estimates
Vertex (VRTX) delivered earnings and revenue surprises of -3.79% and 1.72%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: VRTX
Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: ADCT
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report
Agenus’ BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025
Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year.
Mentions: ANIP
Enphase Energy Stock Sinks on Weaker-Than-Expected Results, Expected Tariffs Hit
Shares of Enphase Energy fell sharply in premarket trading Wednesday, a day after the solar and battery systems provider's first-quarter results fell short of analysts' estimates and it warned of an expected hit to gross margins because of tariffs on China.
Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025
Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation
Agenus (AGEN) Q4 2024 Earnings Call Transcript
AGEN earnings call for the period ending December 31, 2024.
Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
